10 New Contenders for S&P 500 Index

Page 5 of 5

6. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Number of Hedge Fund Holders: 67

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 new contenders for S&P 500 Index.

On April 17, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) provided an update on its experimental drug, ALN-4324. Currently in its Phase 2 clinical trial, the company’s experimental RNAi therapeutic drug aims at treating type 2 diabetes. The trial involves a triple-blind, placebo-controlled study that evaluates the impact of a single subcutaneous injection on insulin sensitivity. Formally initiated in March 2026, the trial reflects Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s strategic expansion from rare diseases into the high-demand metabolic market. If the trial turns out to be successful, it will elevate the company’s position as a formidable competitor, on par with industry leaders like Eli Lilly and Novo Nordisk.

In a separate event, on April 13, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) saw an adjustment to its price target from Truist. The firm lowered its price target from $515 to $505 while maintaining a Buy rating on the stock. Truist provided the update as part of its Q1 results preview among Biotech stocks. The firm further told investors that management anticipates strong annual growth but cautions about Q1 seasonal weakness due to payer dynamics and fewer shipping weeks.

Founded in 2002, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biopharmaceutical company. Based in Massachusetts, the company develops and commercializes novel therapeutics based on ribonucleic acid interference (RNAi).

While we acknowledge the potential of ALNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALNY and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see the 5 New Contenders for S&P 500 Index.

Disclosure: None. Follow Insider Monkey on Google News.

Page 5 of 5